Differential roles of matrix metalloproteinase-9 and -2, depending on proliferation or differentiation of retinoblastoma cells

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 3, 2010, Pages 1783-1788

  Kim, Jeong Hun ^a   Kim, Jin Hyoung ^a   Cho, Chang Sik ^a   Jun, Hyoung Oh ^a   Kim, Dong Hun ^b   Yu, Young Suk ^a   Kim, Kyu Won ^a  

^a Seoul National University   (South Korea)

^b Soonchunhyang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; FIBROBLAST GROWTH FACTOR 2; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NUCLEOSIDE DIPHOSPHATE KINASE NM23; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; BOVINE SERUM ALBUMIN; MITOGEN ACTIVATED PROTEIN KINASE 6; NME1 PROTEIN, HUMAN;

ALBUMIN BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NEURITE; NEUROFILAMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETINOBLASTOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CELL SURVIVAL; DISEASE MODEL; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; RETINA TUMOR; TUMOR CELL CULTURE;

ANIMALS; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; FIBROBLAST GROWTH FACTOR 2; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASE 6; NEURITES; NM23 NUCLEOSIDE DIPHOSPHATE KINASES; RETINAL NEOPLASMS; RETINOBLASTOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SERUM ALBUMIN, BOVINE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR CELLS, CULTURED;

EID: 77949887727     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-3990     Document Type: Article

References (22)

1. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA. 1971;68:820-823.
2. Kim CJ, Chi JG, Choi HS, et al. Proliferation not apoptosis as a prognostic indicator in retinoblastoma. Virchows Arch. 1999;434: 301-305.
3. Dyer MA, Bremner R. The search for the retinoblastoma cell of origin. Nat Rev Cancer. 2005;5:91-101.
4. Kopelman JE, McLean IW, Rosenberg SH. Multivariate analysis of risk factors for metastasis in retinoblastoma treated by enucleation. Ophthalmology. 1987;94:371-377.
5. Shields CL, Shields JA, Baez KA, Cater J, De Potter PV. Choroidal invasion of retinoblastoma: metastatic potential and clinical risk factors. Br J Ophthalmol. 1993;77:544-548.
6. Shields CL, Shields JA, Baez KA, et al. Optic nerve invasion of retinoblastoma: metastatic potential and clinical risk factors. Cancer. 1994;73:692-698.
7. Finger PT, Harbour JW, Karcioglu ZA. Risk factors for metastasis in retinoblastoma. Surv Ophthalmol. 2002;47:1-16.
8. Laurie NA, Donovan SL, Shih CS, et al. Inactivation of the p53 pathway in retinoblastoma. Nature. 2006;444:61-66.
9. Chen D, Livne-Bar I, Vanderluit JL, Slack RS, Agochiya M, Bremner R. Cell-specific effects of RB or RB/p107 loss on retinal development implicate an intrinsically death-resistant cell-of-origin in retinoblastoma. Cancer Cell. 2004;5:539-551.
10. Johnson DA, Zhang J, Frase S, Wilson M, Rodriguez-Galindo C, Dyer MA. Neuronal differentiation and synaptogenesis in retinoblastoma. Cancer Res. 2007;67:2701-2711.
11. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2:161-174.
12. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000;18:1135-1149.
13. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metast Rev. 2006;25:9-34.
14. Adithi M, Nalini V, Kandalam M, Krishnakumar S. Expression of matrix metalloproteinases and their inhibitors in retinoblastoma. J Pediatr Hematol Oncol. 2007;29:399-405.
15. Kim JH, Kim JH, Yu YS, Kim DH, Kim CJ, Kim KW. Establishment and characterization of a novel, spontaneously immortalized retinoblastoma cell line with adherent growth. Int J Oncol. 2007;31: 585-592.
16. Kim JH, Kim JH, Yu YS, Kim DH, Kim CJ, Kim KW. Antitumor activity of arsenic trioxide on retinoblastoma: cell differentiation and apoptosis depending on arsenic trioxide concentration. Invest Ophthalmol Vis Sci. 2009;50:1819-1823.
17. Kim SM, Choi KY, Cho IH, et al. Regulation of dendritic spine morphology by SPIN90, a novel Shank binding partner. J Neurochem. 2009;109:1106-1117.
18. Krishnakumar S, Lakshmi A, Shanmugam MP, Vanitha K, Biswas J. Nm23 expression in retinoblastoma. Ocul Immunol Inflamm. 2004;12:127-135.
19. Clagett-Dame M, McNeill EM, Muley PD. The role of all-trans retinoic acid in neurite outgrowth and axonal elongation. J Neurobiol. 2006;66:739-756.
20. Eggert A, Ikegaki N, Liu X, et al. Molecular dissection of TrkA signal transduction pathways mediating differentiation in human neuroblastoma cells. Oncogene. 2000;19:2043-2051.
21. Kim JH, Kim JH, Yang E, Park JH, Yu YS, Kim KW. Shank 2 expression coincides with neuronal differentiation in the developing retina. Exp Mol Med. 2009;41:236-242.
22. Giuliano M, Vento R, Lauricella M, Calvaruso G, Carabillo M, Tesoriere G. Role of insulin-like growth factors in autocrine growth of human retinoblastoma Y79 cells. Eur J Biochem. 1996; 236:523-532.